![Open Letter to Gavi, vaccine manufacturers and donor governments ahead of the Global Vaccination Summit in Brussels | Médecins Sans Frontières Access Campaign Open Letter to Gavi, vaccine manufacturers and donor governments ahead of the Global Vaccination Summit in Brussels | Médecins Sans Frontières Access Campaign](https://msfaccess.org/sites/default/files/styles/teaser_multi_column_background_480x410/public/2020-01/pneumonia_greece_vaccine_2019_sophia_apostolia_msf266397_3800px.jpg.webp?itok=xd_4kymd)
Open Letter to Gavi, vaccine manufacturers and donor governments ahead of the Global Vaccination Summit in Brussels | Médecins Sans Frontières Access Campaign
![Preclinical in vitro and in vivo profile of a highly-attenuated, broadly efficacious pneumolysin genetic toxoid - ScienceDirect Preclinical in vitro and in vivo profile of a highly-attenuated, broadly efficacious pneumolysin genetic toxoid - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0264410X20305818-gr2.jpg)
Preclinical in vitro and in vivo profile of a highly-attenuated, broadly efficacious pneumolysin genetic toxoid - ScienceDirect
![Resurgence of pneumococcal meningitis in Europe and Northern America - Clinical Microbiology and Infection Resurgence of pneumococcal meningitis in Europe and Northern America - Clinical Microbiology and Infection](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f05829a9-302e-43ce-a2c0-a10da0c0bcd8/gr1_lrg.jpg)
Resurgence of pneumococcal meningitis in Europe and Northern America - Clinical Microbiology and Infection
![Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study | Clinical and Vaccine Immunology Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study | Clinical and Vaccine Immunology](https://journals.asm.org/cms/asset/16a400c5-97ae-4bfe-87d9-38f01cb07c17/cvi.2016.23.issue-12.largecover.jpg)
Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study | Clinical and Vaccine Immunology
![Polysaccharide conjugate vaccine: A kind of vaccine with great development potential - ScienceDirect Polysaccharide conjugate vaccine: A kind of vaccine with great development potential - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1001841720305969-ga1.jpg)
Polysaccharide conjugate vaccine: A kind of vaccine with great development potential - ScienceDirect
Improving vaccines against <italic toggle='yes'>Streptococcus pneumoniae</italic> using synthetic glycans
![Rotavirus spike protein ΔVP8* as a novel carrier protein for conjugate vaccine platform with demonstrated antigenic potential for use as bivalent vaccine | Scientific Reports Rotavirus spike protein ΔVP8* as a novel carrier protein for conjugate vaccine platform with demonstrated antigenic potential for use as bivalent vaccine | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-01549-z/MediaObjects/41598_2021_1549_Fig1_HTML.png)
Rotavirus spike protein ΔVP8* as a novel carrier protein for conjugate vaccine platform with demonstrated antigenic potential for use as bivalent vaccine | Scientific Reports
![Enabling Lyophilized Pneumococcal Conjugate Vaccines Through Formulation Design and Excipient Selection Suitable for A Multivalent Adjuvanted Vaccine - Journal of Pharmaceutical Sciences Enabling Lyophilized Pneumococcal Conjugate Vaccines Through Formulation Design and Excipient Selection Suitable for A Multivalent Adjuvanted Vaccine - Journal of Pharmaceutical Sciences](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/5cee15d4-e36a-4c4c-a468-beda3a339bf4/gr1.jpg)
Enabling Lyophilized Pneumococcal Conjugate Vaccines Through Formulation Design and Excipient Selection Suitable for A Multivalent Adjuvanted Vaccine - Journal of Pharmaceutical Sciences
![Vaccines | Free Full-Text | An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives | HTML Vaccines | Free Full-Text | An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives | HTML](https://www.mdpi.com/vaccines/vaccines-10-00819/article_deploy/html/images/vaccines-10-00819-g001.png)
Vaccines | Free Full-Text | An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives | HTML
Certificat de înregistrare al medicamentului - nr. 21663 din 23.04.2015 Anexa 1 Prospect: Informaţii pentru utilizator Synflor
![Developing vaccines in the era of genomics: a decade of reverse vaccinology - Clinical Microbiology and Infection Developing vaccines in the era of genomics: a decade of reverse vaccinology - Clinical Microbiology and Infection](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/dc0d58df-b40f-49ad-8461-82c4874be0e0/gr1.jpg)
Developing vaccines in the era of genomics: a decade of reverse vaccinology - Clinical Microbiology and Infection
![Enabling Lyophilized Pneumococcal Conjugate Vaccines Through Formulation Design and Excipient Selection Suitable for A Multivalent Adjuvanted Vaccine - Journal of Pharmaceutical Sciences Enabling Lyophilized Pneumococcal Conjugate Vaccines Through Formulation Design and Excipient Selection Suitable for A Multivalent Adjuvanted Vaccine - Journal of Pharmaceutical Sciences](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/29518260-fe23-40b6-bb39-04763a754f4d/gr2_lrg.jpg)